edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs.
In this webinar, CEO Eric Adams and CFO Bruce Colwill present an overview of the company’s recent operating and financial activities. A brief Q&A session follows the presentation.
Get access to the very latest content matched to your personal investment style.